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Introduction 
 
Chronic lymphocytic leukemia (CLL) is a cancer characterized by the uncontrolled proliferation 
and accumulation of B-cell lymphocytes 18. It is the most commonly diagnosed leukemia in the 
Western world 32. In 2017, it is estimated that over 20,000 cases will be diagnosed in the United 
States, comprising of approximately a third of newly diagnosed leukemias 33. Age-adjusted 
incidence rates are especially high for the 65 and older population, at 20.6 per 100,000 34. Such 
elderly patients are also particularly prone to adverse outcomes driven by comorbidity 35. While 
CLL prognosis varies, its beginning is often asymptomatic and insidious 30, 32. Therefore, CLL 
detection is contingent on regular checkups and blood tests, and as such, its epidemiological 
prevalence is likely to be underestimated. While the onset of CLL is gradual, as its name 
suggests, it nevertheless poses economic strain on both the healthcare system and individual 
patients while lowering their qualities of life 31. For these reasons, CLL is an important public 
health consideration with significant social and economic costs.  
While CLL remains non-curative, progress has been made to better manage the disease. Earliest 
breakthroughs in treatment include the use of alkylating agents such as chlorambucil, which 
continues to be used in combination with other therapies 37. Alkylating agents remained the 
standard of care between the 1950s and 1980s, after which fludarabine, a purine nucleoside 
analogue, was introduced in CLL therapy 36. Notable studies determined fludarabine’s advantage 
over chlorambucil with respect to response rates and remission duration, and it soon became a 
mainstay of CLL treatment 38, 39. Immunochemotherapy entered serious therapeutic consideration 
for CLL when rituximab was introduced at the turn of the century. Rituximab targeted CD20 on 
the surface of B-cells and was incorporated into landmark combination therapies with 
fludarabine and cyclophosphamide 36. These combination therapies have since become some of 
the standard approaches to CLL treatment. More recent findings have established the role of B-
cell receptor (BCR) signaling in CLL survival, migration, and proliferation 40. There are a 
number of clinically relevant BCR kinases in CLL. They include phosphatidylinositide-3-kinase 
(PI3K), Lck/Yes novel tyrosine kinase (LYN), Bruton's tyrosine kinase (BTK), and spleen 
tyrosine kinase (SYK) 41, 42. The inhibitors of kinases involved in BCR signaling pathways, such 
as Ibrutinib and Idelalisib, BTK and PI3K inhibitors respectively, have emerged as especially 
promising therapies 43, 44. At this time, these BCR kinases are the subjects of extensive research 
toward the development of novel therapies.  
The origin of CLL manifestations may be sourced from a variety of gene mutations, but are 
divided into two main subtypes. These are classified by the degree of mutations in the variable 
regions of the heavy chain coding segments of the Ig antibody 19. CLL cells are also identified by 
uncharacteristic ZAP-70 expression, which are typically found in T-cells, contributing to their 
activation 20. In malignant B-cells, it is thought that ZAP-70 contributes to cellular activation on 
a similar axis as antigenic engagement does 21. CLL B-cells can also be recognized by the 
presence of surface markers CD19, CD5, and CD23. There are also reduced levels of surface 
IgM, IgD, and CD79b on CLL B-cells, a state which resembles that of an activated and mature 
B-lymphocyte state 22.  
While the historical view of CLL is that it is caused by an initial apoptotic defect, more recent 
findings contradict this view. It is now understood that initial CLL apoptotic evasion may be a 
result of environmental signals 22. Thus, the disease is exacerbated by survival signals provided 
by stromal cells in protective niches, such as the lymph nodes and bone marrow 2, 3. Under 
typical conditions, these survival signals are necessary for healthy B-cell growth and maturation. 
On the other hand, in CLL, the environmental signals rescue neoplastic B-cells from apoptosis 
and allow them to thrive 1, 2, 3, 4. Some of these soluble mediators include tumor necrosis factor 
receptor (TNFR) superfamily ligands- clusters of differentiation ligand 40 (CD40L), B-cell 
activating factor (BAFF), and a proliferation-inducing ligand (APRIL). CD40L and 
BAFF/APRIL are ubiquitously secreted in the stromal niches and promote the survival and 
activation of neoplastic clones 2. BAFF/APRIL ligands and their receptors are indispensable in 
B-cell survival 9, 10, 11, 12. BAFF/APRIL share homology and can bind to two TNFRs – B-cell 
maturation antigen (BCMA) and transmembrane activator of the calcium modulator and 
cyclophilin ligand-interactor (TACI), whereas BAFF alone can bind BAFF receptor (BAFF-R, 
BR3) 13.  
Despite progress in understanding the role of BAFF/APRIL signaling in healthy and neoplastic 
B-cells, the role of BAFF-mediated NFκB activation in CLL remains understudied. 
An important mechanism through which the BAFF and APRIL survival factors work is in the 
activation of Bcl-2 family proteins 13. This system contains pro-apoptotic and anti-apoptotic 
proteins that are maintained in a balanced fashion. B-cells transducing survival signals from 
extrinsic factors in their microenvironments encourage the activity of anti-apoptotic proteins of 
the Bcl-2 family, pushing the balance toward survival 23. If the pro-apoptotic proteins Bak and 
Bax are uninhibited to a threshold degree, they oligomerize and permeabilize the mitochondrial 
membrane 23. This initiates the release of caspase-activating factors such as cytochrome c into 
the cytoplasm, which results in the cleavage of cellular proteins and leads to cell death. This 
response, however, is inhibited by the anti-apoptotic proteins, which indicates that the Bcl-2 
family proteins can be harnessed to promote both cell survival and cell death.  
There are a number of pathways that mediate survival factors expressed by stromal cells and 
apoptosis avoidance through the Bcl-2 protein family. CLL cells in the microenvironments of the 
lymph node, for example, display gene signatures that indicate the activation of the BCR and 
nuclear factor-κB (NFκB) pathways 5. The therapeutic inhibition of BCR-associated kinases has 
significantly impacted CLL outcomes, in part, by causing B-cell migration from niches that 
provided stromal support 6. However, patients who progress on, or are intolerant of BCRi 
therapy, have poor outcomes 7, 8. Improved understanding of microenvironment signaling 
through other pathways will foster development of novel therapeutic approaches in CLL. This 
work focuses on one such pathway, the NFκB signaling pathway. Like other TNFR ligands, 
BAFF/APRIL activate NFκB signaling. This is a major common pathway which mediates anti-
apoptotic responses in CLL cells through induction of Bcl-2 family proteins and chemokine 
networks 13, 14, 15, 16, 17. Both signal through BCMA/TACI to activate the canonical NFκB in CLL, 
where the IκB kinase complex phosphorylates IκB , triggering its ubiquitination and leading to 
nuclear translocation of the NFκB dimers, predominantly p50/RelA and p50/c-Rel 9, 14. This, in 
turn, leads to a survival response.  
BAFF also works through non-canonical NFκB signaling and can be initiated via the BAFF 
receptor, also known as BR3. Its activation mechanism via the BAFF/BR3 interaction will be 
delineated as follows. When BR3 is stimulated by the BAFF ligand, it frees the NF-κB inducing 
kinase (NIK) to phosphorylate the IκB kinase (IKKα). NIK also directly phosphorylates p100 at 
two sites: Ser-866 and Ser-870. IKKα activation via NIK phosphorylates p100 at the Ser-822 site 
24. Once all three serine sites are phosphorylated, p100 is processed into p52, dimerizes with 
RelB, enters the nucleus, and initiates the transcription of pro-survival BCL-2 family proteins 24.  
Of note, there is a particular mechanism by which NIK is activated to initiate phosphorylation of 
IKKα and p100. The non-canonical BAFF signaling pathway is constantly repressed 25. When no 
ligand is attached to the BAFF receptor, NIK is constitutively targeted for ubiquitination and 
then degraded 25. Cellular inducer of apoptosis proteins (cIAPs) 1 and 2 are responsible for the 
ubiquitination of NIK 26. However, cIAP does not perform its function autonomously. It first 
binds to tumor necrosis factor receptor-associated factor 2 (TRAF2), leading to dimerization 
with TRAF3, which is bound to NIK. The association of TRAF3 and NIK is known to be 
essential to NIK degradation 25. The TRAF2 and TRAF3 complex allows cIAP to ubiquitinate 
NIK 26. This constant process prevents NIK from being active.  
Activation of NIK requires that TRAF 3 must be inhibited 26. During BAFF receptor activation, 
the receptor recruits TRAF 3, TRAF 2, and cIAP to its receptor domain 27. At this point, cIAP 
ubiquitinates TRAF 3 and target it for degradation 26. Consequentially, without TRAF 3, NIK 
accumulates until it is energetically favored to phosphorylate IKKα and p100 27. Preliminary 
experiments have suggested that BAFF stimulation has also upregulated the phosphorylation of a 
protein from a different pathway, which aids in cell survival. BAFF stimulation is not only 
working through the non-canonical NFκB pathway, but is likely involved in crosstalk with the 
BCR pathway through SYK. This investigation focuses on the mechanism of this crosstalk. 
Since NIK is activated in response to BAFF stimulation, it is possible that NIK is also inducing a 
BCR response through phosphorylation of SYK. The mechanism of this crosstalk is the subject 
of investigation.  
 
 
 
Methods 
 
Patient samples and cell culture 
Peripheral blood was obtained from patients with CLL at the Center for Hematologic 
Malignancies at the Oregon Health and Science University (Portland, OR) after informed 
consent. Mononuclear cells were isolated using standard Ficoll-Hypaque techniques (Amersham, 
Piscataway, NJ), rendering >90% CD5+/CD19+ cells, as determined by flow cytometry 
(FACSCanto). CLL cells were cultured in RPMI-1640 supplemented with 15% fetal bovine 
serum, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 25 mM HEPES, 100 
μM non-essential amino acids and 1 mM sodium pyruvate (Life Technologies, Grand Island, 
NY). For stimulation with soluble factors, CLL cells were seeded at 1x106/mL in the presence of 
25 ng/mL soluble human BAFF (sol-BAFF; Cell Signaling Technology, Danvers, MA).   
For stimulation with stroma, BAFF-expressing Chinese hamster ovary cells (BAFF-CHO) were 
obtained from Dr. Robert Woodland (University of Massachusetts, Worcester, MA) 18. The cells 
were maintained in MEM-α supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 
100 μg/mL streptomycin, and 1 μM non-essential amino acids.  CHO-K1 cells not expressing 
BAFF were used as control (American Type Culture Collection [ATCC], Manassas, VA).  
CLL cells were cultured on BAFF-expressing (or control) cells under the stromal conditions 
previously described 17. Briefly, stromal cells were seeded to achieve 80-100% confluence; on 
the following day, CLL cells were plated at a 50:1 ratio and incubated at 370C in 5% CO2. 
Cultures were then treated with drugs as indicated. At harvest, CLL cells were gently washed off 
the stromal layer. When harvested for protein, CLL cells were transferred to a new plate and 
incubated for an additional 60 minutes to allow re-attachment of stromal cells, before the CLL 
cells were gently washed off and collected. This minimized contamination of CLL cells by the 
adherent BAFF-expressing or control cells.  
 
Immunoblotting and Immunoprecipitation (IP) 
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris, 150 mM NaCl, 
1% NP-40, 1 mM NaF, 1 mM Sodium phosphate, 1 mM NaVO3, 1 mM EDTA, 1 mM EGTA), 
supplemented with protease inhibitor cocktail (Roche, Indianapolis, IN), phosphatase inhibitor 
cocktail 2 and 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich).  
For immunoprecipitation experiments, cell protein lysates were pre-cleared and incubated at 4ºC 
overnight with 2 g of the indicated primary antibody or with rabbit IgG as isotype-specific 
control (Santa Cruz Biotechnology, Santa Cruz, CA). Lysates were incubated with 20 μL of 50% 
protein A agarose beads slurry (Cell Signaling) for 3 hours at 4ºC. After washes, samples were 
heated to 95ºC for up to 5 min and analyzed by immunoblotting. 10% of source protein was used 
as input control.  
The following antibodies were used: GAPDH, IKKα, NIK, NFκB2(p100/52), pSYKY352, SYK 
(#2712), SYK (D3Z1E, for IP), TRAF2, TRAF3 (Cell Signaling Technology, Danvers, MA); β-
actin (Sigma-Aldrich). 
 
Cell electroporation 
Raji cells (ATCC) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 100 
U/mL penicillin and 100 μg/mL streptomycin. Electroporation of Raji cells was performed using 
the Amaxa Human B-cell Nucleofection Kit (Lonza, Walkersville, MD). 5x106 cells were mixed 
with 100 µL of Amaxa Solution V, and 2 µg of DNA was nucleofected using program O-017. 
Transfection efficiency, assessed by transfection with 2 µg pMaxGFP plasmid, was 70-90% with 
cell viability of >90% at 24 hours. pCMV4-NIK-HA was a gift from Shao-Cong Sun (Addgene 
plasmid 27554) 21. 
 
Results 
 
 
Figure 1. SYK interacts with NIK/TRAF2/TRAF3 in neoplastic B-cells. (A-B) Raji cells were 
stimulated with 25 ng/mL sol-BAFF for 30 min. Proteins lysates were subjected to 
immunoprecipitation experiments using indicated antibodies as described in the methods. A 
representative blot of three independent experiments is shown. (C) Raji cells were transfected 
with siNIK vs. control siRNA. 48 h later, cells were stimulated with 25 ng/mL sol-BAFF for 30 
min. Whole-cell lysates were subjected to immunoblotting. A representative blot of three 
independent experiments is shown. 
 
 
Figure 2. SYK-TRAF2/3 interaction. (A, C) Raji cells were stimulated with 25 ng/mL sol-
BAFF for 30 min. Proteins lysates were subjected to immunoprecipitation experiments with 
TRAF2 or control antibodies. (B, C) CLL cells were cultured on BAFF-expressing stroma for 24 
h. Protein lysates were immunoprecipitated with SYK or control antibodies. Representative blots 
of three independent experiments are shown. (D) Raji cells were transfected with pCMV-NIK or 
control plasmid. 48 h later, cells were stimulated or not with 25 ng/mL sol-BAFF for 30 min. 
Whole-cell lysates were subjected to immunoblotting. A representative blot of three independent 
experiments is shown. (E) CLL cells were co-cultured with BAFF-expressing stroma for 24 h, 
followed by treatment with IKK inhibitors for 6h. Whole cell protein lysates were subjected to 
immunoblotting. 
 
 
 
Figure 3. BAFF-BCR crosstalk in CLL cells. BAFF-R engagement stabilizes NIK within the 
NIK/TRAF2/TRAF2/cIAP1/2 complex, promoting the non-canonical NFκB pathway activity. 
SYK recruitment to NIK/TRAF2/TRAF3 signaling complex assists BAFF-mediated activation 
of BCR signaling, which contributes to activation of the canonical NFκB. Concurrently, SYK 
induces STAT3 transcription factor, thereby upregulating Mcl-1, a pro-survival Bcl-2 family 
member.  
 
BAFF stimulation induces SYK interaction through the NIK/TRAF2/TRAF3 signaling complex 
Since we found that BAFF promotes CLL cell survival via SYK-mediated upregulation of the 
canonical NFκB and Mcl-1, we studied how BAFF activates SYK. BAFF-R signals through an 
intermediary complex, which involves adaptor proteins TRAF2/TRAF3, NFκB-inducing kinase 
(NIK), and inhibitor of apoptosis (IAP) family proteins cIAP1/2 13. While the exact mechanism 
remains elusive, it is believed that in unstimulated B-cells NIK is constitutively bound to TRAF3 
and degraded. When BAFF-R is engaged, the NIK/TRAF/cIAP complex is recruited to the 
receptor, followed by TRAF3 repression, thus allowing NIK to persist and activate IKK1. IKK1 
catalyzes proteasome-assisted processing of NFκB2 (p100) precursor, thereby inducing the non-
canonical NFκB 13. Since targeting NEDD8 with pevonedistat, which blocks p100 processing 17, 
did not regulate Mcl-1 in BAFF-stimulated CLL cells, we supposed that NIK and/or IKK1 may 
be responsible for BAFF-induced SYK activation. To study this, we evaluated whether SYK 
complexes with NIK/TRAF2/TRAF3 in Raji B-cell lymphoma cell line. Immunoprecipitation of 
cells with SYK monoclonal antibodies showed association of SYK with TRAF3 and TRAF2 in 
BAFF-stimulated Raji cells (Fig. 1A). Moreover, we were able to detect NIK in our SYK 
immunoprecipitates. Conversely, TRAF2 co-immunoprecipitated with both SYK and NIK in 
Raji cells, while SYK complexed with TRAF2 and TRAF3 in primary CLL cells (Fig. 2A-C). 
We subsequently confirmed SYK binding in the reverse experiments with NIK monoclonal 
antibodies (Fig. 1B). By contrast, SYK did not complex with IKK1 in either Raji or CLL cells 
(Fig. 1A and Fig. 2B-C), strongly suggesting that SYK interacts with submembrane TRAFs in 
neoplastic B-cells.  
As in CLL, BAFF stimulation induced SYK phosphorylation in Raji cells. However, engineered 
expression of NIK failed to enhance SYK activation either in the absence or in the presence of 
BAFF (Fig. 2D). A possible explanation for this is the critical requirement for TRAF2/3 scaffold 
in NIK-SYK interaction: NIK depletion by means of a genetic knockdown did result in reduced 
SYK activation (Fig. 1C). Meanwhile, pharmacologic targeting of IKKs failed to prevent BAFF-
mediated SYK activation (Fig. 2E). 
Thus, BAFF-BCR crosstalk in neoplastic B-cells is at least in part mediated by SYK interaction 
with NIK/TRAF2/TRAF3 complex (Fig. 3).  
 
Discussion 
 
Along with the BCR, many concurrently active pathways ensure survival of the neoplastic B-
cells in the protective niche. Others have previously demonstrated that primary CLL cells co-
cultured with CD40L-expressing stroma activate the canonical and non-canonical NFκB 
pathways, accompanied by upregulation of the pro-survival Bcl-2 family proteins (Bcl-xL), and 
acquire therapeutic resistance, including to BCRi’s 15, 16, 17. BAFF was previously shown to co-
opt BCR signaling in mouse splenic B-lymphocytes, manifested by phosphorylation of the BCR-
associated CD79A subunit and SYK 28. Here we propose a possible mechanism that facilitates 
this cross-talk in primary human neoplastic B-cells (Fig. 3).  
We observed direct interaction between NIK/TRAF2/TRAF3 complex and SYK in CLL cells, 
potentially implicating those two kinases in BAFF-BCR cross-talk in neoplastic B-cells (Fig. 3). 
However, we have not investigated the role of the BCR structures (CD79A/B) or LYN, a BCR-
associated kinase constitutively active in CLL cells 29, in this setting. Additional experiments 
will be required to decipher the exact contributions of the individual kinases and BCR structural 
components in BAFF-BCR cross-talk in CLL, and will be hampered by the technical challenges 
of eliminating those individual players in primary B-cells. It is conceivable that multiple 
conditions need to be fulfilled, where cooperative action involving an intact BCR structure and 
the SRC family protein kinases is required for NIK-mediated activation of SYK and BCR signal 
propagation.  
Subsequent studies should help elucidate the exact ligand-receptor interactions leading to BCR 
activation in CLL. BAFF and APRIL bind the two TNFR superfamily members - BCMA and 
TACI - with high affinity. It would be important to confirm whether APRIL stimulation could 
replicate some of the BAFF ligand effects. While our data suggest that BAFF-BR3 interaction 
may be necessary for BCR activation via NIK/TRAF2/TRAF3 complex, isolated and concurrent 
blockade of the individual signaling receptors 10 will be necessary to elucidate their importance 
in regulation of NFκB and BCR signaling pathways, as well as response to BCRi in BAFF-
simulated CLL cells. 
Thus, this study illuminates the cross-talk between BAFF and BCR signaling pathways in 
neoplastic B-cells and provides insights into the mechanism of the interaction.   
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